What is the recommended management for a patient with endoscopic grade A esophagitis?

Management of Grade A Esophagitis

For patients with endoscopically confirmed Los Angeles Grade A esophagitis, initiate once-daily proton pump inhibitor (PPI) therapy, assess response at 4-8 weeks, then wean to the lowest effective dose or on-demand therapy with H2 blockers/antacids for long-term management. 1

Initial Treatment Approach

• Start with standard-dose PPI once daily as first-line therapy, which has strong evidence for healing esophagitis and providing symptomatic relief 2
• PPIs are significantly more effective than H2-receptor antagonists (H2RAs), which are in turn more effective than placebo for healing erosive esophagitis 2, 3
• Assess treatment response at 4-8 weeks 1

Grade A Esophagitis: A Borderline Phenotype

Grade A esophagitis represents "borderline GERD" rather than conclusive severe disease 1. This classification is important because:

• Patients with LA Grade A esophagitis fall into an intermediate category when acid exposure time (AET) is ≥4.0% but doesn't meet criteria for conclusive GERD 1
• Only LA Grade B or higher esophagitis constitutes conclusive GERD evidence 1
• This borderline status influences long-term management strategy, favoring therapy de-escalation when possible 1

Dose Escalation for Non-Responders

If symptoms persist after 4-8 weeks on once-daily PPI:

• First verify medication compliance before escalating therapy 1
• Increase to twice-daily PPI dosing (though not FDA-approved, this is supported by expert consensus based on pharmacodynamics) 2
• Alternatively, switch to a more effective acid suppressive agent 1
• Avoid adding nocturnal H2RA to twice-daily PPI as there is no evidence of improved efficacy with this combination 2

Long-Term Management Strategy

For patients who respond to initial PPI therapy:

• Wean to the lowest effective dose that controls symptoms 1
• Consider converting to on-demand therapy if symptoms remain controlled during dose reduction 1
• On-demand therapy can utilize H2 blockers or antacids for rapid symptom relief 1
• Patients requiring chronic PPI therapy beyond one year should undergo reflux testing off PPI to determine appropriateness of lifelong therapy 1

Adjunctive Lifestyle Modifications

Target specific lifestyle modifications based on individual symptom patterns rather than broadly enforcing all recommendations 2:

• Weight loss for overweight/obese patients may prevent or postpone need for acid suppression 2
• Elevate head of bed for patients with nighttime heartburn or regurgitation despite medical therapy 2
• Avoid specific trigger foods (alcohol, coffee, spicy foods) only if patient consistently experiences symptoms after ingestion 2
• Avoid recumbency for 2-3 hours after meals 2

When to Perform Follow-Up Endoscopy

• Repeat endoscopy is NOT routinely indicated for Grade A esophagitis after treatment response 4
• Repeat endoscopy after 8+ weeks of PPI therapy is suggested only for severe erosive esophagitis (LA Grade C or D) to exclude Barrett's esophagus or dysplasia 4
• Consider endoscopy if symptoms fail to respond to twice-daily PPI therapy to evaluate for alternative diagnoses 2, 4

Common Pitfalls to Avoid

• Do not routinely obtain biopsies from endoscopically normal tissue to diagnose GERD or exclude Barrett's esophagus in adults 4
• Avoid metoclopramide as monotherapy or adjunctive therapy, as it is not recommended due to fair evidence of ineffectiveness or harm outweighing benefits 2
• Do not continue escalating PPI doses beyond twice-daily without further diagnostic evaluation, as this represents treatment failure 2
• Remember that most PPI efficacy data comes from once-daily dosing studies, even though twice-daily dosing is commonly used in clinical practice 2